RusnanoMedInvest: Funding, Team & Investors

RusnanoMedInvest functions as a venture capital firm, primarily directing strategic investments into the pharmaceutical and biotechnology sectors. It focuses on identifying and funding innovative developments across life sciences and healthcare technology, often employing a co-investment model to support companies creating advanced therapeutic and diagnostic solutions.

Founded in 2012, RusnanoMedInvest originated as a strategic partnership between RUSNANO, a significant Russian state-owned corporation, and the US venture fund Domain Associates. This collaboration was driven by the insight to channel capital into global, particularly American, life sciences companies, aiming to advance medical technologies that could benefit the Russian healthcare landscape.

The firm's "customers" are the innovative pharmaceutical and biotechnology companies receiving its investment capital and strategic oversight. The broader vision is to accelerate the introduction of novel medical products and therapies. Ultimately, RusnanoMedInvest seeks to enhance healthcare outcomes by bringing pioneering scientific advancements to market, addressing unmet medical needs and improving patient care.

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Apr 1, 2017	Epic Sciences	$40.0M Series D	Jerry Xiao	Deerfield Management, Domain Associates, Altos Capital Partners, Frederic PLA, Pagoda Investment, Reach Tone Limited, Sabby Capital, VI Ventures
Jan 1, 2017	Binx Health	$35.0M Series D	—	Earlybird Venture Capital, EQT Life Sciences, HealthCap, OrbiMed, BB Biotech Ventures, DRX Capital, Johnson & Johnson Innovation, LSP, Technology Venture Partners, Wondfo Biotech
Aug 1, 2015	Syndax Pharmaceuticals	$80.0M Series C	Delos, Fidelity Management & Research Company	Amoon Fund, Domain Associates, InterWest, Osage University Partners, T1D Fund, Vivo Capital, Arrowpoint Partners, Biomed Ventures, Cormorant Asset Management, EcoR1 Capital, Forward Ventures, Greenwood Capital, Jennison Associates, MPM Capital, OrbiMed, Tavistock Group
Jan 1, 2015	Binx Health	$20.0M Series C	—	Earlybird Venture Capital, HealthCap, BB Biotech Ventures, Johnson & Johnson Innovation, LSP, Novartis, South West Ventures Fund
Sep 1, 2014	Clearside Biomedical	$16.0M Series B	—	Hatteras Venture Partners, Georgia Research Alliance, Mountain Group Partners, Santen Pharmaceutical
Aug 1, 2014	ALDEA Pharmaceuticals	$24.0M Series B	—	Canaan Partners, Omega Funds, Canaan Partners, Correlation Ventures, WuXi AppTec
Jul 1, 2014	Epic Sciences	$30.0M Series C	—	Deerfield Management, Domain Associates, Arcus Ventures, Pfizer, Roche
Feb 12, 2014	Miramar Labs	$10.0M Series D	—	Aisling Capital, Cross Creek Advisors, Domain Associates, Morgenthaler Ventures
Oct 3, 2013	NovaDigm Therapeutics	$14.0M Series B	Domain Associates, Rusnanomedinvest	—
Aug 1, 2013	Syndax Pharmaceuticals	$27.0M Series B	—	Amoon Fund, Domain Associates, InterWest, Osage University Partners, T1D Fund, Vivo Capital, Forward Ventures, MPM Capital
Jan 1, 2013	Marinus Pharmaceuticals	$21.0M Series C	—	Canaan Partners, Domain Associates, Canaan Partners, Foundation Medical Partners, Sofinnova Investments
Dec 1, 2012	Regado Biosciences	$51.0M Series E	Rusnanomedinvest	Domain Associates, Aurora Funds, Baxter Ventures, Caxton Advantage, Quaker Partners
Jul 1, 2012	Ocunexus Therapeutics	$20.0M Series B	—	Domain Associates, Kleiner Perkins, Versant Ventures, Biopacificventures, GBS Venture Partners

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Apr 1, 2017	Epic Sciences	$40.0M Series D	Jerry Xiao	Deerfield Management, Domain Associates, Altos Capital Partners, Frederic PLA, Pagoda Investment, Reach Tone Limited, Sabby Capital, VI Ventures
Jan 1, 2017	Binx Health	$35.0M Series D	—	Earlybird Venture Capital, EQT Life Sciences, HealthCap, OrbiMed, BB Biotech Ventures, DRX Capital, Johnson & Johnson Innovation, LSP, Technology Venture Partners, Wondfo Biotech
Aug 1, 2015	Syndax Pharmaceuticals	$80.0M Series C	Delos, Fidelity Management & Research Company	Amoon Fund, Domain Associates, InterWest, Osage University Partners, T1D Fund, Vivo Capital, Arrowpoint Partners, Biomed Ventures, Cormorant Asset Management, EcoR1 Capital, Forward Ventures, Greenwood Capital, Jennison Associates, MPM Capital, OrbiMed, Tavistock Group
Jan 1, 2015	Binx Health	$20.0M Series C	—	Earlybird Venture Capital, HealthCap, BB Biotech Ventures, Johnson & Johnson Innovation, LSP, Novartis, South West Ventures Fund
Sep 1, 2014	Clearside Biomedical	$16.0M Series B	—	Hatteras Venture Partners, Georgia Research Alliance, Mountain Group Partners, Santen Pharmaceutical
Aug 1, 2014	ALDEA Pharmaceuticals	$24.0M Series B	—	Canaan Partners, Omega Funds, Canaan Partners, Correlation Ventures, WuXi AppTec
Jul 1, 2014	Epic Sciences	$30.0M Series C	—	Deerfield Management, Domain Associates, Arcus Ventures, Pfizer, Roche
Feb 12, 2014	Miramar Labs	$10.0M Series D	—	Aisling Capital, Cross Creek Advisors, Domain Associates, Morgenthaler Ventures
Oct 3, 2013	NovaDigm Therapeutics	$14.0M Series B	Domain Associates, Rusnanomedinvest	—
Aug 1, 2013	Syndax Pharmaceuticals	$27.0M Series B	—	Amoon Fund, Domain Associates, InterWest, Osage University Partners, T1D Fund, Vivo Capital, Forward Ventures, MPM Capital
Jan 1, 2013	Marinus Pharmaceuticals	$21.0M Series C	—	Canaan Partners, Domain Associates, Canaan Partners, Foundation Medical Partners, Sofinnova Investments
Dec 1, 2012	Regado Biosciences	$51.0M Series E	Rusnanomedinvest	Domain Associates, Aurora Funds, Baxter Ventures, Caxton Advantage, Quaker Partners
Jul 1, 2012	Ocunexus Therapeutics	$20.0M Series B	—	Domain Associates, Kleiner Perkins, Versant Ventures, Biopacificventures, GBS Venture Partners

RusnanoMedInvest

Subscribe, Save or Share

About

Investment Activity

Investments Made

Financial History

Investment Activity

Investments Made